Biotech and Pharmaceuticals Pharmaceuticals

More

  • WASHINGTON, July 27- Teva Pharmaceutical Industries Ltd won U.S. antitrust approval to purchase Allergan Plc's generics business, after agreeing to divest 79 generic drugs to rival firms, the Federal Trade Commission said on Wednesday. "Millions of Americans rely daily on generic drugs to treat a wide range of illnesses," Debbie Feinstein, director of the FTC's...

  • NEW YORK— Israeli drugmaker Teva, the largest generic drug company in the world, said Wednesday it expects to complete its $40.5 billion purchase of the generic drug business of competitor Allergan next week after federal regulators approved the deal. The FTC said Allergan runs the third-largest generics company in the U.S. That business previously belonged...

  • WASHINGTON, July 27- Teva Pharmaceutical Industries Ltd won U.S. antitrust approval to purchase Allergan Plc's generics business, after agreeing to divest more than 75 generic drugs to rival firms, the Federal Trade Commission said on Wednesday. The $40.5 billion deal, which was announced in July 2015, solidifies Teva's position as the world's No. 1 maker of...

  • July 27- Eli Lilly& Co will likely step up the pace of making deals with other drugmakers while aggressively developing new drugs on its own, the company's newly appointed chief executive said on Wednesday. Company veteran David Ricks will become CEO on Jan. 1, after John Lechleiter, 62, retires by year-end, the Indianapolis- based drugmaker said.

  • WASHINGTON, July 27- Teva Pharmaceutical Industries Ltd won U.S. antitrust approval to purchase Allergan Plc's generics business, after agreeing to divest more than 75 generic drugs to rival firms, the Federal Trade Commission said on Wednesday.

  • MRI image of brain showing area of Alzheimer patient.

    TauRx's drug LMTX failed to improve cognitive and functional skills in patients with mild to moderate Alzheimer's, a study showed.

  • *Government says decision a clear vote of confidence in UK. LONDON, July 27- GlaxoSmithKline plans 275 million pounds of new investments at three drug manufacturing sites in Britain, signalling its confidence in the country despite last month's vote to leave the European Union. GSK is investing in sites at Barnard Castle, in the north of England, Montrose, in...

  • GSK CEO on Brexit

    CNBC's Meg Tirrell breaks down GlaxoSmithKline's quarterly results and provides highlights from CEO Andrew Witty comments to CNBC Europe on Brexit.

  • July 27- U.S. drugmaker Eli Lilly and Co said on Wednesday John Lechleiter, its chief executive of eight years, would retire by the end of the year and would be succeeded by senior vice president David Ricks on January 1. Earnings growth at the Indianapolis- based drugmaker resumed last year after three years of tumbling sales. The company's internal pipeline is...

  • Eli Lilly Chairman and CEO John C. Lechleiter will retire in December after leading the drugmaker through a challenging period in which it lost U.S. patent protection for several top-selling products. Lechleiter focused on developing new drugs, as opposed to making big acquisitions, to grow the company's business, and the new CEO will benefit from that, said...

  • LONDON, July 27- Demand for new medicines helped GlaxoSmithKline grow earnings in the second quarter and the drugmaker is set for big gains in the rest of 2016 thanks to a weak pound, after Britain's vote to leave the European Union. GSK, whose outgoing chief executive Andrew Witty had backed Britain staying in the EU, will benefit from the fact that many of its costs...

  • LONDON, July 27- GlaxoSmithKline has bought global rights to an experimental drug from Johnson& Johnson for up to 175 million pounds, raising its bet on a new generation of biotech medicines for severe asthma. The British drugmaker recently launched Nucala, its first injectable biological asthma drug, and is looking for additional treatments to help more...

  • Very happy with second quarter performane: GSK CEO

    Andrew Witty, CEO of GlaxoSmithKline, comments on the company's earnings which beat expectations, with sales up 11 percent.

  • Bio electronics has great potential: GSK CEO

    Andrew Witty, CEO of GlaxoSmithKline, says the firm has been investing in bio electronic medicine for the last few years.

  • We're getting on with life after Brexit: GSK CEO.

    Andrew Witty, CEO of GlaxoSmithKline, explains why he was opposed to Brexit but adds that everything is now business as usual at the company.

  • John Lechleiter, Chairman, president and CEO of Eli Lily.

    Eli Lilly on Monday announced that John Lechleiter, its chairman, president and CEO, will retire from the company effective December 31, 2016.

  • Government says decision a clear vote of confidence in UK. LONDON, July 27- GlaxoSmithKline plans 275 million pounds of new investments at three drug manufacturing sites in Britain, signaling its confidence in the country despite last month's vote to leave the European Union. Britain's biggest drugmaker, which had argued against Brexit before the referendum,...

  • LONDON— Pharmaceutical company GlaxoSmithKline announced plans Wednesday to invest some 275 million pounds into three plants in Britain, sweeping aside concerns about growth following the country's decision to leave the European Union. Chief Executive Andrew Witty said that Britain's "competitive corporate tax system" and skilled workforce...

  • WASHINGTON— A senior senator is examining whether Medicare's prescription drug benefit is vulnerable to manipulation by pharmaceutical companies that set very high prices for medications. Grassley acted after The Associated Press reported on Medicare data that show spending for high-cost drugs covered under the program's "catastrophic" protection...

  • Government says decision a clear vote of confidence in UK. LONDON, July 27- GlaxoSmithKline plans 275 million pounds of new investments at three drug manufacturing sites in Britain, signalling its confidence in the country despite last month's vote to leave the European Union. Britain's biggest drugmaker, which had argued against Brexit before the...